Bristol-Myers Squibb Company
FGF-21 FORMULATIONS

Abstract:

The present application provides pharmaceutical formulations comprising a FGF-21 polypeptide, e.g., a modified FGF-21 polypeptide such as PEG-FGF-21, and one or more stabilizers such as the chelator DPTA. The formulations can be can further stabilized by including a surfactant such as polysorbate 80 and/or adjusting the pH to about 7.1. Also provided are methods of manufacture, methods of treatment, and kits.